Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell

 

August 5, 2016 — Here are the top 20 most popular current content on the Diagnostic and Interventional...

Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016 | Dave Fornell

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in...

News | Antiplatelet and Anticoagulation Therapies | July 26, 2016

July 26, 2016 — Hematology researchers at The Children’s Hospital of Philadelphia (CHOP) have developed a novel...

BBMK Technologies, ClotMD mobile app, real-time warfarin management
Technology | Antiplatelet and Anticoagulation Therapies | July 14, 2016

July 14, 2016 — BBMK Technologies recently announced the launch of ClotMD, a cloud-based application and mobile...

Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016

July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. will...

pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies | July 26, 2016 | Heidi Olson, Pharm.D

With the recent introduction of several novel oral...

beta-blockers, Thomas Jefferson University, beta-adrenergic receptors

Selective activation of the beta2-adrenergic receptor (beta2AR) by a beta-arrestin-biased pepducin promotes activation of a beta-arrestin signaling pathway that is cardioprotective. Image courtesy of the lab of Jeffrey Benovic, Thomas Jefferson University.

News | Heart Failure | June 30, 2016

June 30, 2016 — Researchers at Thomas Jefferson University have discovered how to enhance the effectiveness of beta-...

anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies | May 25, 2016

May 25, 2016 — Technavio’s latest report on the U.S....

Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders | May 20, 2016 | Dave Fornell

Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater...

News | Atrial Fibrillation | May 19, 2016

May 19, 2016 — Physician-researchers in the College of Medicine at the University of Cincinnati have developed a...

clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies | May 19, 2016 | Marianne Pop, Pharm.D., BCPS

 

There were many opinions on the duration of dual antiplatelet therapy (DAPT) highlighted at the 2016...

A Medtronic CoreValve TAVR device being deployed under angiographic image guidance.

 

Feature | Heart Valve Technology | May 16, 2016

May 16, 2016 — The largest observational study of percutaneous transfemoral transcatheter aortic valve replacement (...

PROMETHEUS, anticoagulation in women
News | Antiplatelet and Anticoagulation Therapies | May 16, 2016

May 16, 2016 – Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute...

Overlay Init